Expression of BRCA1 is commonly decreased in sporadic breast tumors, and this correlates with poor prognosis of breast cancer patients. Here we show that BRCA1 transcripts are selectively enriched in the Argonaute/miR-182 complex and miR-182 downregulates BRCA1 expression. Antagonizing miR-182 enhances BRCA1 protein levels and protects them from IR-induced cell death, while overexpressing miR-182 reduces BRCA1 protein, impairs homologous recombination-mediated repair, and render cells hypersensitive to IR. The impaired DNA repair phenotype induced by miR-182 overexpression can be fully rescued by overexpressing miR-182-insensitive BRCA1. Consistent with a BRCA1-deficiency phenotype, miR-182-overexpressing breast tumor cells are hypersensitive to inhibitors of poly (ADP-ribose) polymerase 1 (PARP1).
INTRODUCTION
Germline mutations or deletions in breast cancer susceptibility gene BRCA1 contribute to familial breast tumor formation, but there is limited evidence for direct mutation of the BRCA1 gene in the sporadic form of the disease. However, decreased expression of the BRCA1 gene has been shown to be common (30%-65%) in sporadic basal-like breast cancer, and the magnitude of the decrease correlates with disease progression (Mueller and Roskelley, 2003; Thompson et al., 1995; Turner et al., 2004 Turner et al., , 2007 Wilson et al., 1999) . Because sporadic tumors account for $90% of the total breast cancer burden, a key question that emerges is how BRCA1 expression is suppressed in these tumors.
DNA methylation, which can be permanent and heritable, is associated with decreased tumor suppressor gene expression in a number of disease contexts (Herman and Baylin, 2000) . Although promoter methylation may result in very low levels of BRCA1, aberrant methylation of the BRCA1 promoter is found only in a relatively moderate percentage (10%-15%) of sporadic breast tumors (Catteau et al., 1999; Esteller et al., 2000; Matros et al., 2005; Rice et al., 2000) , and there is no significant correlation with clinical or pathological parameters of the disease (Matros et al., 2005) . Other factors which have been reported to potentially contribute to diminished BRCA1 expression are the transcriptional suppressors ID4 (Turner et al., 2007) and HMGA1 (Baldassarre et al., 2003) . However, it is still unclear how BRCA1 silencing occurs in the majority of sporadic basallike breast tumors.
From a therapeutic perspective, the expression level of BRCA1 is a major determinant of response to different classes of chemotherapy (Mullan et al., 2006) . BRCA1-deficient tumors are hypersensitive to DNA damaging chemotherapeutic agents (such as cisplatin, mitomycin C, etc.) (Bhattacharyya et al., 2000; Fedier et al., 2003; Moynahan et al., 2001) . Based on the principle of ''synthetic lethality,'' BRCA mutation-associated cancers with impaired homologous recombination (HR)-mediated repair of DNA double-strand breaks (DSBs), are being selectively targeted by inhibitors of the DNA repair protein PARP1 (Bryant et al., 2005; Farmer et al., 2005) . Conversely, the presence of functional BRCA1 sensitizes tumor cells to antimicrotubule agents (such as vincristine, paclitaxel) (Fedier et al., 2003; Mullan et al., 2001 ). Therefore, the cellular level of BRCA1 can directly impact malignant transformation and therapeutic response.
Because other DNA repair factors have recently been reported to be regulated by microRNAs (miRNAs) (Crosby et al., 2009; Lal et al., 2009) , we hypothesized that specific miRNAs may suppress BRCA1 expression in breast tumors. miRNAs are small ($22 nt) noncoding RNAs that regulate posttranscriptional gene expression by blocking translation of target mRNAs or by accelerating their degradation (Bartel, 2009; Fabian et al., 2010) . Although studies addressing their role in cancer pathogenesis are at an early stage, it is apparent that loss-or gain-of-function of specific miRNAs contributes to cellular transformation and tumorigenesis (Chang and Mendell, 2007; Garzon et al., 2009; Ventura and Jacks, 2009) . Using the experimental system of in vitro hematopoietic cell differentiation and miRNA expression analysis, we have recently discovered that miRNAs downregulate DSB repair factors and suppress DNA repair in terminally differentiated blood cells (Lal et al., 2009) . Our goal was to identify miRNAs targeting BRCA1 and other DSB factors using this same strategy.
RESULTS

Radiation
Response of MicroRNA Cluster-183 in Dividing and Postmitotic Cells In order to identify the differentiation-induced miRNAs that play a role in the DNA damage response, proliferating progenitor K562 cells and postmitotic differentiated K562 cells (cells were treated with 12-O-tetradecanoylphorbol-13-acetate [TPA] to produce terminally differentiated megakaryocytes) were exposed to IR, and the expression of miRNAs was studied by microarray analysis. We were particularly interested in the IR response of a subset of miRNAs that have previously been shown to be upregulated in multiple blood lineages (Lal et al., 2009) . We hypothesized that in postmitotic blood cells DNA damage induces apoptosis and miRNAs attenuate the DSB repair machinery promoting cell death. Therefore, the expression of these miRNAs would be indifferent to IR in postmitotic cells. However, upon irradiation of proliferating progenitor cells, we postulated that these miRNAs are downmodulated to allow increased production of DNA repair proteins and boost the DNA damage response. Following exposure to IR, only five miRNAs were downregulated >2-fold in the proliferating K562 cells, but not in the postmitotic cells (see Figure S1A available online). Three of the miRNAs in this set, miR-96, miR-183, and miR-182, are encoded in an $5 kb gene segment. They are processed from a well-conserved polycistronic transcript on human chromosome 7q32.2 ( Figure S1B ). These miRNAs (termed miRNA cluster-183) have a sensory role (Lewis et al., 2009; Mencia et al., 2009) and are expressed at high levels in mouse retina and sensory hair cells of the ear (Friedman et al., 2009; Jin et al., 2009; Pierce et al., 2008; Xu et al., 2007) . miRNA cluster-183 is aberrantly expressed in a variety of tumors (Bandres et al., 2006; Gaur et al., 2007; Hanke et al., 2009; Lowery et al., 2010; Segura et al., 2009; Watkins et al., 2010; Zhang et al., 2006) and is potentially useful for tumor classification (Gaur et al., 2007) . We verified the microarray results by qRT-PCR. miR-183, miR-96, and miR-182 were significantly upregulated during terminal differentiation of HL60 and K562, (Figure 1A) . As expected, there was no significant change in expression of miRNA cluster-183 in differentiated cells exposed to IR ( Figure S1C ). However, there was a sharp decrease in expression of miR-96, miR-183, and miR-182 in undifferentiated HL60 cells ( Figure 1B ) within 30 min of IR exposure. Importantly, the expression levels diminished in an IR dosage-dependent manner. The rapid and dramatic change in expression of these miRNAs in response to IR suggests a possible involvement in the DNA damage response.
miR-182 Targets BRCA1
We had postulated that miRNA cluster-183 was rapidly downregulated in response to IR in dividing cells to allow increased production of DNA repair factors. In order to identify DNA repair factors targeted by these miRNAs we adopted a computational approach. Several of the available prediction algorithms (such as TargetScan and Pictar) are largely based on evolutionary conservation of target sites across species (Bartel, 2009; Sethupathy et al., 2006) . However several critical DSB repair factors (such as MDC1, 53BP1, DNA-PK, BRCA1, and BRCA2) are not found in lower eukaryotes, potentially making these algorithms less effective in identifying DNA repair targets. We used RNA22, which is distinct from other methods in that it obviates the use of a cross-species sequence conservation filter, thus allowing the discovery of miRNA binding sites that may not be present in closely related species (http://cbcsrv.watson.ibm. com/rna22.html) (Miranda et al., 2006) . One limitation of this method is that it predicts hundreds or even thousands of potential targets for each miRNA, making it difficult to identify the most important targets. The problem was further compounded by the fact that we had three miRNAs, and there was a cumulative list of targets. We therefore focused on miR-182, which was predicted to target BRCA1. miR-182 is predicted to target several DSB repair proteins ( Figure S1D ), which include BRCA1, NHEJ1/XLF, etc. However, bioinformatic algorithms have a high margin of error, and the majority of predicted genes may not be real targets (Sethupathy et al., 2006) . To screen predicted targets, we adapted a recently described (Easow et al., 2007; Hendrickson et al., 2008; Karginov et al., 2007) biochemical approach ( Figure 1C ). miRNAs target their corresponding mRNAs in association with a protein complex that includes the Argonaute proteins, AGO1 and AGO2. This interaction allows for the identification of miRNAtarget interactions that occur in vivo. Immunoprecipitation (IP) of a hemagglutinin (HA)-tagged AGO1 can recover miRNA/ mRNA complexes. In cells that overexpress a specific miRNA, IP of HA-AGO1 selectively enriches for the overexpressed miRNA and its corresponding target mRNAs. Using this strategy, we found that the miR-182/AGO1 complex associates selectively with the BRCA1 transcript ( Figure 1C ) at levels comparable with a validated miR-182 target, FOXO3 mRNA (Segura et al., 2009) . Levels of BRCA1 mRNA were significantly higher than control transcripts (5S rRNA and GAPDH mRNA) and other predicted targets (NHEJ1 mRNA). The BRCA1 3 0 UTR is ($1400 nt) long and has four potential miR-182 miRNA recognition elements (MREs) ( Figure S1E ), and MRE #3 is the most conserved. It is important to note that none of these four sites have perfect complementarity to the ''seed'' sequence. To verify that BRCA1 is regulated by miR-182, we used the luciferase reporter assay. Luciferase activity was reduced $2-fold by miR-182 expression in cells transfected with wild-type (WT) BRCA1-reporter. Mutation of the predicted MREs completely restored luciferase expression ( Figure 1D ). Furthermore, we tested the efficacy of each individual MRE and luciferase activity was suppressed to varying degrees by MREs #1, #3, and #4, but MRE#2 had no impact on luciferase activity ( Figure 1E ). Together these results suggest that miR-182 targets the BRCA1 transcript directly by interaction with its 3 0 UTR.
miR-182-Mediated Suppression of BRCA1 Impedes DNA Repair Next, we looked at BRCA1 expression levels after ectopic overexpression of miR-182 and observed a significant decrease in BRCA1 protein ( Figure 2A ). Importantly, overexpression of miR-183 and miR-96, which are coexpressed with miR-182, did not affect BRCA1 protein levels. The physiological relevance of the BRCA1/miR-182 interaction was further established by evaluating the endogenous expression pattern of miR-182 and BRCA1. miR-182 is overexpressed in the course of hematopoietic differentiation. If miR-182 is regulating BRCA1 levels, then the prediction would be that BRCA1 levels diminish in parallel with increasing expression of miR-182. We differentiated HL60 cells to granulocytes using DMSO and monitored the expression levels of miR-182 and BRCA1 over 8 days. Consistent with our prediction, we observed a striking inverse correlation of BRCA1 protein levels, with miR-182 expression ( Figure 2B ). Together these results suggest that BRCA1 is a physiologically relevant target of miR-182. BRCA1 is an integral component of the cellular DNA damage response (Boulton, 2006; Huen et al., 2010) . To determine whether miR-182-mediated BRCA1 downregulation affects DNA repair, we measured the persistence of DSBs after IR, as an indicator of unrepaired damaged DNA, by single-cell gel electrophoresis (neutral comet assay) ( Figure 2C ). HL60 cells with ectopic overexpression of miR-182 had lower levels of BRCA1 protein and significantly higher residual DNA damage relative to control cells ( Figure 2C , left panel). Conversely, HL60 cells HL60 and K562 cells (data not shown) were exposed to indicate doses of g-radiation and RNA isolated 30 min after exposure. There was significant reduction in miR-183 (p < 0.002), miR-96 (*p < 0.003), and miR-182 (*p < 0.002) at 3 Gy. In all the above experiments (A and B), the expression of miR-183, miR-96, and miR-182 was analyzed with qRT-PCR and normalized to RNU6B, mean ± SD, n = 3-6 independent experiments, are shown. (C) Isolation of target transcripts associated with miR-182. HeLa cells were cotransfected with expression vectors for HA-tagged AGO1 and miR-182/miR-scr. The immunoprecipitated RNA was analyzed by qRT-PCR using gene-specific primers and normalized to 5S rRNA. FOXO3 and GAPDH served as positive and negative controls, respectively. BRCA1, and not NHEJ1, was significantly (p < 0.002) enriched in the pull-down. (D and E) miR-182 targets the 3 0 UTR of BRCA1 mRNA in a luciferase reporter assay. HeLa cells were cotransfected with BRCA1 3 0 UTR-luciferase reporter, wild-type (WT, stripped), or mutant (M, gray) (D), or with the four predicted miR-182 MREs in the BRCA1 3 0 UTR (E) and control mimic (miR-scr, black) or miR-182 mimic (stripped and gray) for 48 hr before analysis. Firefly luciferase activity of the reporter was normalized to an internal Renilla luciferase control. Mean ± SD of three independent experiments is shown. miR-182 significantly (p < 0.001) suppresses lucifererase activity from BRCA1-WT reporter, but mutation in the miR-182 recognition sites in BRCA1-M rescues this suppression (p < 0.001).
differentiated with DMSO, and transfected with miR-182 antisense oligonucleotides (termed antagomirs, ASO) had significantly lower amounts of DNA breaks and higher levels of BRCA1 protein ( Figure 2C , right panel).
miR-182 Expression Impacts HR-Mediated Repair
DSBs are one of the most deleterious types of damage caused by radiation (Jackson and Bartek, 2009) . Two major pathways, HR and nonhomologous end-joining (NHEJ), have evolved to deal with DSBs, and the critical components of these pathways are conserved from yeast to mammals (Shrivastav et al., 2008) . BRCA1 is involved in the HR-mediated DSB repair pathway (Moynahan et al., 1999) , and recent reports suggest that it may impact the pathway choice (Bouwman et al., 2010; Bunting et al., 2010; Cao et al., 2009) . To test whether expression of miR-182 impacts HR repair, we assayed for HR-mediated repair of an I-SceI-induced DSB, in U2OS cells, using a recombination substrate DR-GFP (Nakanishi et al., 2005) . Consistent with the role of BRCA1 in HR (Moynahan et al., 1999; San Filippo et al., 2008) , cells overexpressing miR-182 had significantly reduced HR efficiency ( Figure 2D ). The cumulative impact of BRCA1 deficiency on cellular DNA damage response is increased sensitivity to IR and other DNA damaging agents (Moynahan et al., 2001; Scully et al., 1999) . Manipulating miR-182 levels (via mimics or antagomirs) in HeLa cells impacts sensitivity to IR ( Figure 2E) . Importantly, the effect of miR-182 on IR sensitivity was fully rescued by overexpressing miR-182-insensitive BRCA1.
Together these results suggest that miR-182-mediated downregulation of BRCA1 impedes the DNA damage response.
miR-182 Levels Correlate with BRCA1 Expression in Breast Tumor Lines BRCA1 expression affects both breast tumor development and therapy (Mullan et al., 2006; Narod and Foulkes, 2004; Palacios et al., 2008) . Based on molecular profiling of tumors, breast cancer types have been divided into those with high expression miR-182 expression and representative FACS profiles are shown. HR repair was significantly (p < 0.002) impaired (lower panel). Mean ± SD of three independent experiments is shown. (E) BRCA1 mediates the DNA damage sensitivity induced by miR-182. Cells were mock transfected, transfected with miR-182 antagomir (ASO), transfected with miR-182 mimic or BRCA1 cDNA lacking the 3 0 UTR or both. Cell viability was assayed after indicated doses of g-radiation by clonogenic cell survival assay.
Curves were generated from three independent experiments. miR-182 mimic significantly (p < 0.003) enhanced sensitivity to IR, whereas miR-182 ASO reduced (p < 0.001) IR sensitivity. Representative immunoblots for (D) and (E) are shown.
of the ER gene (luminal) and those that do not express ER (basal) (Perou et al., 2000) . ER-negative status is an intrinsic feature of BRCA1-related breast cancer (Atchley et al., 2008; Foulkes et al., 2004) . We investigated BRCA1 protein and miR-182 expression in a panel of breast cancer lines derived from ERpositive and -negative sporadic tumors ( Figure 3A) . Consistent with clinical data, the basal-like ER-negative cell lines 21NT, BT549, HS578T, and HCC38 had relatively low levels of BRCA1 protein (Neve et al., 2006) . Interestingly, in five of the six ER-negative cell lines there was inverse correlation of BRCA1 protein and miR-182 expression ( Figure 3B ). To test whether the cell cycle profile contributes to this correlation, we compared the cell cycle profile of HS578T (no correlation of BRCA1 protein and miR-182) with three other ER-negative cell lines ( Figure 3C ). Interestingly, HS578T has a very distinct profile with a mixed diploid and polyploid cell population (Zajac et al., 2008) . Finally, in synchronized 21NT cells we examined the rela- tive expression of miR-182 and BRCA1 in the course of the cell cycle ( Figure 3D ). As described previously (Gudas et al., 1996; Shrivastav et al., 2008) , BRCA1 expression increases with entry into S phase. Interestingly, miR-182 is coexpressed with BRCA1 during the cell cycle. This is consistent with a report by Bartel and colleagues (Shkumatava et al., 2009 ) in which they show that miRNAs and their biologically important target transcripts are coexpressed. Together these results suggest that miR-182 may regulate BRCA1 expression during the cell cycle and that their correlation may depend on cellular DNA content.
BRCA1 Is Targeted by miR-182 in Breast Tumor Lines
The physiological relevance of the BRCA1/miR-182 interaction was further established by evaluating the endogenous expression pattern of miR-182 and BRCA1 in postmitotic breast epithelial cells. It has been reported that TPA treatment of breast cancer lines leads to a postmitotic state (Cunliffe et al., 2003) , and we confirmed this result ( Figure S2 ). We treated MCF7 cells with TPA and monitored the expression levels of miR-182 and BRCA1 over 3 days. Consistent with our expectation, we observed a striking inverse correlation of BRCA1 protein levels, with miR-182 expression ( Figure 4A) . Like blood cells, upon IR treatment there was rapid and dosage-dependent decrease of miR-182 expression in proliferating MCF7 cells, but not postmitotic MCF7 cells ( Figure 4B ). Relative decrease in miR-182 levels with IR exposure in MCF7 cells is comparable to levels in primary human mammary epithelial cells (HMECs, data not shown). Interestingly, the decrease in miR-182 is specific to IR and exposure of MCF7 cells to other DNA damaging agents, UV (single strand breaks/crosslinks) and camptothecin (replication stress), does not impact miR-182 levels ( Figure 4C ).
miR-182 Influences the DNA Damage Response in Breast Tumor Lines
To determine whether miR-182-mediated BRCA1 downregulation in breast cancer lines affects DNA repair, we overexpressed miR-182 in MDA-MB231 cells (low endogenous miR-182, high BRCA1 protein) and reduced miR-182 expression in 21NT cells (high endogenous miR-182, low BRCA1 protein). MDA-MB231 cells with ectopic overexpression of miR-182 had lower levels of BRCA1 protein and significantly higher residual DNA damage relative to control cells ( Figure 4D, left panel) . Conversely, 21NT cells transfected with miR-182-(ASO) had higher levels of BRCA1 protein and significantly lower amounts of DNA breaks ( Figure 4D, right panel) . Together these results suggest that BRCA1 is a physiologically relevant target of miR-182 in breast cancer cells.
To determine the therapeutic impact of miR-182-mediated regulation of BRCA1 in breast cancer, we overexpressed miR-182 in MDA-MB231 cells and reduced miR-182 expression in 21NT cells and assessed their sensitivity to IR. Consistent with the DNA repair assays, MDA-MB231 cells overexpressing miR-182 were significantly more sensitive to different doses of IR ( Figure 5A, left panel) . Importantly, the effect of miR-182 on IR sensitivity was fully rescued by overexpressing miR-182-insensitive BRCA1, further confirming that miR-182 impacts the radiosensitivity of breast tumor cells via BRCA1. Furthermore, antagonizing miR-182 expression in 21NT by miR-182-(ASO) induced significant radio resistance in these cells ( Figure 5A , right panel). Together these results strongly suggest that miR-182-mediated downregulation of BRCA1 significantly impacts the radiation response of breast cancer cells.
miR-182 Impacts PARP Inhibitor Sensitivity HR deficiency of BRCA mutation-associated breast tumors selectively sensitizes them to PARP1 inhibitors (Bryant et al., 2005; Farmer et al., 2005) , which is a working therapeutic 
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strategy to eliminate these tumors (Fong et al., 2009; Tutt et al., 2010) . Since miR-182 influences HR-mediated repair ( Figure 2D ) we speculated that miR-182 expression will impact cellular sensitivity to PARP1 inhibitors. Overexpressing miR-182 diminished BRCA1 levels and sensitized MDA-MB231 cells to PARP1 inhibition ( Figure 5B , left panel) using the PARP1 inhibitors 4-amino-1, 8-naphthalimide (ANI) and ABT-888 (data not shown). This effect is reverted by expressing miR-182-insensitive BRCA1 transcripts. Conversely, reducing miR-182 enhanced BRCA1 expression and induced resistance to ANI ( Figure 5B , right panel) and ABT-888 (data not shown) in 21NT cells. Next we tested if the clinical PARP inhibitor olaparib can retard outgrowth of miR-182-expressing tumors. We treated mice 2 days after injection or those bearing xenografts, derived from MDA-MB-231 cells either stably expressing miR-182 or scramble control ( Figure S3) , with olaparib or vehicle control (right panels) were transfected with either control ASO or 182 ASO. Cell viability was assayed by clonogenic cell survival assay after indicated doses of g-radiation (A) or in the presence of PARP1 inhibitor (ANI) at indicated concentrations (B). Curves were generated from three independent experiments. miR-182 mimic significantly enhanced sensitivity to IR (p < 0.004) and to ANI (p < 0.001), whereas miR-182 ASO reduced sensitivity to IR (p < 0.001) and ANI (p < 0.002). Representative immunoblots for (A) and (B) are shown.
(C) miR-182 impacts PARP inhibitor sensitivity in xenograft mouse models. MDA-MB231 cells stably expressing miR-scr or miR-182 were implanted in each thigh of nude mice (n = 5), and olaparib treatment was initiated either 2 days postimplantation (left panel) or tumors outgrown (4-7 weeks) were treated (right panel). Tumor volume was determined in 7 days intervals and the median fold differences after olaparib treatment represented graphically.
for 10 days. As anticipated, a 10 day treatment with olaparib retarded tumor outgrowth in animals treated both preor posttumor formation ( Figure 5C ). In untreated animals the tumors grew at a comparable rate in the presence or absence of miR-182 ( Figure S4 ). We harvested the tumors and confirmed the expression of miR-182 (data not shown). Altogether, these results convincingly demonstrate that miR-182 is a mediator of the cellular response to PARP inhibitors. Importantly, the observation that the DNA repair-deficient phenotype induced by miR-182 was largely rescued by miR-182-resistant BRCA1 transcripts suggests that the key target of miR-182 in DNA repair is BRCA1.
DISCUSSION
We have previously used the experimental system of in vitro hematopoietic cell differentiation to find miRNAs involved in DSB repair (Lal et al., 2009) , and the same strategy was applied to identify miR-182. A rapid, IR dosage-dependent decrease in miR-182 expression further implicated a role in the DNA damage response. This IR-induced change in miR-182 is independent of p53, as it occurs in both p53-proficient (MCF7, HMEC) as well as p53-deficient (K562, HL60) cells. Using a combination of computational and biochemical methods, we found that BRCA1 was targeted by miR-182. It is feasible that other factors in the DNA damage response are affected by miR-182 expression. However, the observation that the DNA repair-deficient phenotype induced by miR-182 was largely rescued by miR-182-resistant BRCA1 transcripts suggests that the key target of miR-182 in DNA repair is BRCA1.
Decreased expression of the BRCA1 has been shown to be common in sporadic basal-like breast cancer (Mueller and Roskelley, 2003; Turner et al., 2004) . Although the magnitude of the decrease correlates with disease progression, the molecular mechanism of BRCA1 suppression in sporadic tumors is unclear. We anticipate that overexpression of miRNAs such as miR-182 may play a role in BRCA1 downregulation in sporadic breast tumors. Manipulation of miR-182 expression in multiple breast tumor lines impacts BRCA1 levels and sensitivity to PARP1 inhibition, either in cultured cells or in xenograft models. This observation has potential clinical relevance. Although familial breast cancer patients with BRCA mutations are currently being treated with PARP inhibitors, the majority of patients with breast cancer ($90%) have the sporadic form of the disease and do not have BRCA mutations. It is currently unclear if patients with sporadic breast cancer benefit from the therapeutic approach with PARP inhibitors. Our results suggest that sporadic tumors overexpressing miRNAs which target BRCA proteins (such as miR-182) may also be susceptible to PARP inhibition or other strategies based on synthetic lethality with BRCA. Future studies will determine whether expression levels of miR-182 and possibly other miRNAs that regulate BRCA1 can serve as determinants of therapeutic strategy and of clinical outcome for patients with breast cancer.
EXPERIMENTAL PROCEDURES
Cell Culture and Differentiation HL60 cells and K562 cells were grown and differentiated into different lineages as previously described (Lal et al., 2009) . MCF-7 cells (10 6 cells/6 cm dish)
were differentiated with 100 nM TPA for 3 days in DMEM with 10% (v/v) FBS (Cunliffe et al., 2003) . The breast cancer lines and human mammary epithelial cells used in Figure 3 were cultured in media according to protocols from ATCC (http://www.atcc.org/).
miRNA Microarray, RNA Isolation, and Quantitative PCR Undifferentiated and differentiated K562 cells were untreated or exposed to 2 Gy of g-radiation. Total RNA was extracted after 2 hr with Trizol (Invitrogen) according to the manufacturer's manual and treated with 10 U DNase I for 30 min at 37 C in 50 ml. RNase-free water was added and DNase I removed with phenol-choloroform (Ambion). The TaqMan Human MicroRNA Array v 1.0 (Early Access) platform was used for quantitative miRNA analysis and was carried out in the Dana-Farber Cancer Institute core facility. In subsequent experiments, TaqMan MicroRNA Assay from Applied Biosystems was used as per the manufacturer's instructions. mRNA expression was anlayzed by qPCR using SYBR Green master mix (Applied Biosystems) according to the manufacturer's manual and the Bio-Rad iCycler. Gene-specific primers were as follows: BRCA1 F, CAACATGCCCACAGATCAAC, R, ATGGAAGCCATTGTCC TCTG; NHEJ1 F, AGTGCCAAGTGAGGGAGCTA, R, CCACTTGGACCTCTTG TGT; FOXO3 F, GATAAGGGCGACAGCAACAG; R, CCAGTTCCCTCATTCTG GAC; 5S rRNA F, GCCCGATCTCGTCTGATCT; R, AGCCTACAGCACCCGG TATT; GAPDH F, TGCACCACCAACTGCTTAGC; R, GGCATGGACTGTGGT CATGAG; and FNDC3A F, CTTGGAGCTGGTCCTTTCAG; R, CCTTCCCCAG CTTCATTACA. Immunoprecipitation of miR-182 Targets miR-182 was cloned from HL60 cDNA in pcDNA3.1-Puro expression vector (Invitrogen) using the following primers: miR-182, F, CGGCGGCCGCGATAT GAGGGGAAGGGAGGA; R, CGGCGGCCGCGAGAAGGTTCACCACCCAGA. Cells were cotranfected with HA-AGO1 (Addgene) and miR-182 or miR-scr (expression vectors). After 2 days, cells were harvested in 400 ml lyses buffer (100 mM KCl, 5 mM MgCl 2, 10 mM HEPES [pH 7.0], 0.5% Nonidet P-40) containing freshly added RNaseOUT (Invitrogen) and Protease Inhibitor Cocktail (Roche). After centrifugation, a 50 ml aliquot was taken as input for subsequent RNA extraction. The remaining supernatant was gently shaken with HA beads (HA-probe Santa Cruz sc-7392) for 4 hr at 4 C in spin columns (Pierce Spin Columns-Screw Cap). The columns were drained and washed, and the retained beads were treated with 5 U DNaseI in NT2 buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1 mM MgCl 2, 0.05% Nonidet P-40) for 10 min at 37 C, washed, and treated with Proteinase K. Finally the beads were resuspended and RNA extracted using acid phenol-choloroform (Ambion). The analysis was done as follows: scrambled control, pull-down/input (say = A); miR-182, pull-down/input (say = B); fold enrichment = B/A.
Luciferase Assay
The WT and mutated (M) miR-182 recognition elements of 3 0 UTR-BRCA1 were annealed (for sequence, see below) and cloned in pMIR-REPORT (Ambion) downstream to Firefly Luciferase. The luciferase assays were done in HeLa cells as described previously (Lal et al., 2009 ). The primer sequences are as follows: WT F, CTAGTAGAAGAGATTTCTA AAAGTCTGAGATATATTTGCTAGATTTCTAAAGAATGTGTTCTAAAACAGCA GAAGATTTTCAAGAACCGGTTTCCAAAGACAG; WT R, AGCTCTGTCTTTG GAAACCGGTTCTTGAAAATCTTCTGCTGTTTTAGAACACATTCTTTAGAAAT CTAGCAAATATATCTCAGACTTTTAGAAATCTCTT; M F, CTAGAAGAGAC GATACCCGTCTGAGATATATTTGCTAGGCGATACCCGGGTGTGTTCTAAA AGCAGAAGCCGATACCCGGCCGGCGATACCCGACAG; and M R, AGC TCTGTCGGGTATCGCCGGCCGGGTATCGCTTCTGCTGTTTTAGAACACAC CCGGGTATCGCCTAGCAAATATATCTCAGACGGGTATCGCTCTCTTCTAG.
The mutant residues have been indicated. Primers for the individual sites are as follows: (site I) F, CTAGGGAAAATGA AACTAGAAGAGATTTCTAAAAGTCT; R, AGCTAGACTTTTAGAAATCTCTTCT AGTTTCATTTTCC; (site II) F, CTAGAAAGTCTGAGATATATTTGCTAGATTTCT AAAGAATG; R, AGCTCATTCTTTAGAAATCTAGCAAATATATCTCAGACTTT; (site III) F, CTAGAGAATGTGTTCTAAAACAGCAGAAGATTTTCAAGAACCG; R, AGCTCGGTTCTTGAAAATCTTCTGCTGTTTTAGAACACATTCT; (site IV) F, CTAGAAAACAGCAGAAGATTTTCAAGAACCGGTTTCCAAAGACAG; R, AGC TCTGTCTTTGGAAACCGGTTCTTGAAAATCTTCTGCTGTTTT.
Immunoblots
The immunoblots were done as described previously (Lal et al., 2009; Lee et al., 2010) with BRCA1 antibodies 1:500 dilution (CALBIOCHEM, MS110) and tubulin antibodies 1:10000 dilution (Sigma, Clone B-5-1-2).
Single-Cell Gel Electrophoresis, Comet, Assay 21NT cells were transfected with 100 nM, control or miR-182 antagomir (Ambion), whereas MDA-MB231 cells were transfected with 10 nM, control or miR-182 mimic (Ambion). After 3 days, cells were irradiated and allowed to recover for 18 hr prior to analysis. The single cell comet assays (Trevigen) were carried out as previously described (Lal et al., 2009; Lee et al., 2010) .
Homologous Recombination Reporter Assay HR assay was done as described (Chowdhury et al., 2008; Lee et al., 2010) . Briefly, 2 3 10 5 cells plated overnight in 24-well plates were transfected with 0.8 mg of I-SceI expression plasmid (pCBA Sce) using Lipofectamine 2000. Two days later, GFP-positive cells were assayed by FACScan. Cell Cycle Synchronization 21NT cells were seeded on a 6-well plate (2.5 3 10 5 /well) in DMEM 10% FBS media and treated twice with 2 mM thymidine for 16 hr with a 9 hr interval between treatments. Subsequently the cell were released into media containing 100 ng/ml nocadozole and incubated for 12 hr. The cells were washed and released into DMEM 20% FBS media and were collected for FACS analysis and RNA extraction after indicated time intervals. For FACS the cell were fixed in 70% ethanol, washed twice with PBS buffer, and analyzed in PI/RNase staining buffer (BD PharMingen).
Xenograft Experiments
MDA-MB231 cells (2.5 3 106/injection) stably expressing miR-scr or miR-182 from pcDNA3.1(+)Neo were injected subcutaneously into CD1 nude mice. Olaparib (50 mg/kg, obtained in collaboration with AstraZeneca) or vehicle (PBS + 10% DMSO + 10% HPCB) treatment was initiated either at 2 days postinjection or at detectable tumor volume ($70 mm 3 ) between 4 and 7 weeks later.
Each animal obtained ten intraperitoneal injections on 10 consecutive days. Measurement of tumor volume by calipers was commenced 7 days post the subcutaneous injection and continued in 7 day intervals.
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